1053 Preclinical pharmacodynamic characterization of STK-026: a novel IL-12 partial agonist for cancer with maintained CD8 T cell activity, reduced NK-mediated toxicity and an improved therapeutic window

Zhenya Koliesnik; Michael Totagrande; Ryan Burgess; Kim Q Tran; Michele Bauer; Bharghavi Jayaraman; Cindy Buffone; Priyanka Balasubrahmanyam; Jan Emmerich; Deepti Chaturvedi; Deepti Rokkam; Rene De Waal Malefyt; Heiko Greb; Navneet Ratti; Sandro Vivona; Robert Kastelein; Patrick Lupardus; Luis Zuniga; David B Rosen; Martin Oft

doi:10.1136/jitc-2023-SITC2023.1053

Citation Tools

Regular and Young Investigator Award Abstracts

Immune-Stimulants and Immune Modulators

1053 Preclinical pharmacodynamic characterization of STK-026: a novel IL-12 partial agonist for cancer with maintained CD8 T cell activity, reduced NK-mediated toxicity and an improved therapeutic window

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Koliesnik Z, Totagrande M, Burgess R, et al

1053 Preclinical pharmacodynamic characterization of STK-026: a novel IL-12 partial agonist for cancer with maintained CD8 T cell activity, reduced NK-mediated toxicity and an improved therapeutic window

Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.1053

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password